Jeil Pharma Holdings CEO Sangcheol Han increases stake to 10.14% via block trade

Sangcheol Han, CEO and major shareholder of Jeil Pharma Holdings, acquired an additional 70,000 common shares at 7,280 KRW per share via a block trade on June 22, 2026.
This increased his ownership from 9.70% to 10.14%, a rise of 0.44 percentage points, which may be interpreted as a signal of management confidence.
The transaction was made with personal funds and does not affect the company's total outstanding shares or capital structure, resulting in no dilution for existing shareholders.
[AI Summary]The CEO's voluntary stake increase signals management confidence but is unrelated to the company's financial policy changes or capital raising activities. It may positively impact short-term stock sentiment but does not directly alter shareholder value.